Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: Image reconstruction, biological half-lives and sensitivity

NMR in Biomedicine

Volumn 27, Issue 3, 2014, Pages 261-271

  Jacoby, Christoph ^a   Temme, Sebastian ^a   Mayenfels, Friederike ^b   Benoit, Nicole ^c   Krafft, Marie Pierre ^c   Schubert, Rolf ^b   Schrader, Jürgen ^a   Flögel, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

19F chemical shift imaging; Excretion rate; Inflammation imaging; Perfluorocarbons

Indexed keywords

19F CHEMICAL SHIFT IMAGING; EXCRETION RATE; INFLAMMATION IMAGING; PERFLUOROCARBONS;

ANIMALS; EMULSIONS; FLUORINE; FLUOROCARBONS; HALF-LIFE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFLAMMATION; KINETICS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; SIGNAL-TO-NOISE RATIO; SPLEEN; TIME FACTORS; VAPOR PRESSURE;

EID: 84893815032     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3059     Document Type: Article

References (48)

1. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 2005; 23: 983-987.
2. Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, Schubert R, Schrader J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008; 118: 140-148.
3. 19F MRI in vivo. Circ. Cardiovasc. Imaging 2010; 3: 202-210.
4. 19F-magnetic resonance imaging (MRI). PLoS One 2011; 6: e18246.
5. Flögel U, Su S, Kreideweiss I, Ding Z, Galbarz L, Fu J, Jacoby C, Witzke O, Schrader J. Noninvasive detection of graft rejection by in vivo (19)F MRI in the early stage. Am. J. Transplant. 2011; 11: 235-244.
6. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magn. Reson. Med. 2011; 65: 1144-1153.
7. Flögel U, Burghoff S, van Lent PL, Temme S, Galbarz L, Ding Z, El-Tayeb A, Huels S, Bonner F, Borg N, Jacoby C, Muller CE, van den Berg WB, Schrader J. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 2012; 4: 146ra108.
8. 19F MRI). J. Inflamm. (London) 2012; 9: 24.
9. Spahn DR. Blood substitutes. Crit. Care 1999; 3: R91-R92.
10. Riess JG. Oxygen carriers ("blood substitutes") - raison d'Etre, chemistry, and some physiology. Chem. Rev. 2001; 101: 2797-2919.
11. Girard F, Poulet P, Namer IJ, Steibel J, Chambron J. Localized T2 measurements using an OSIRIS-CPMG method. Application to measurements of blood oxygenation and transverse relaxation free of diffusion effect. NMR Biomed. 1994; 7: 343-348.
12. 19F in a rabbit abscess model. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994; 22: 1449-1454.
13. 19F NMR probes of oxygen tension and temperature. J. Magn. Reson. Ser. B 1995; 106: 131-141.
14. 19F NMR imaging of perfluorocarbons. Biomed. Tech. (Berlin) 2002; 47(Suppl 1 Pt 1): 451-454.
15. Thomas SR. The biomedical applications of Fluorine-19 NMR. In: Partain CL, Price RR, Patton JA, Kulkarni MV, James AEJ (eds). Magnetic Resonance Imaging, Vol. 2. W.B. Saunders Co.: London, 1988; 1536-1552.
16. Kong CF, Holloway GM, Parhami P, Fung BM. C-13 and F-19 nuclear magnetic resonance study of perfluoro chemical emulsions. J. Phys. Chem. 1984; 88: 6308-6311.
17. 19F NMR relaxometry of a perfluorocarbon emulsion. Magn. Reson. Med. 1993; 29: 303-310.
18. 2 carrier for second generation blood substitutes. Nouv. J. Chim. 1984; 8: 251-257.
19. Grec CC, Riess JG, Devallez B. Etude de solvants perfluoroalkylés à usage biomédical. Nouv. J. Chim. 1985; 9: 637-643.
20. Riess JG, Krafft MP. Advanced fluorocarbon-based systems for oxygen and drug delivery, and diagnosis. Artif. Cells Blood Substit. Immobil. Biotechnol. 1997; 25: 43-52.
21. Marie Bertilla S, Thomas JL, Marie P, Krafft MP. Cosurfactant effect of a semifluorinated alkane at a fluorocarbon/water interface: impact on the stabilization of fluorocarbon-in-water emulsions. Langmuir 2004; 20: 3920-3924.
22. 19F magnetic resonance imaging of perfluorooctylbromide. Magn. Reson. Med. 2010; 63: 1119-1124.
23. Cornélus C, Krafft MP, Riess JG. Improved control over particle sizes and stability of concentrated fluorocarbon emulsions by using mixed fluorocarbon/hydrocarbon molecular dowels. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994; 22: 1183-1191.
24. Baas JMA, Vandegraaf B, Tavernier D, Vanhee P. Empirical force field calculations: conformational analysis of cis-decalin. J. Am. Chem. Soc. 1981; 103: 5014-5021.
25. 19F magnetic resonance imaging of perfluorooctyl bromide in vivo. Magn. Reson. Imaging 1988; 6: 61-64.
26. Meyer KL, Carvlin MJ, Mukherji B, Sloviter HA, Joseph PM. Fluorinated blood substitute retention in the rat measured by F-19 magnetic resonance imaging. Invest. Radiol. 1992; 27: 620-627.
27. Barker BR, Mason RP, Peshock RM. Echo planar imaging of perfluorocarbons. Magn. Reson. Imaging 1993; 11: 1165-1173.
28. 19F-NMR imaging in vivo using FLASH-MRI. Magn. Reson. Imaging 1994; 12: 149-153.
29. 19F MRI of a perfluorooctyl bromide emulsion: application to a dynamic biodistribution study and oxygen tension mapping in the mouse liver and spleen. NMR Biomed. 2012; 25: 654-660.
30. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007; 21: 1647-1654.
31. Lai CS, Stair SJ, Miziorko H, Hyde JS. Effect of oxygen and the lipid spin label Tempo-laurate on F-19 and proton relaxation rates of the perfluorochemical blood substitute, FC-43 emulsion. J. Magn. Reson. 1984; 57: 447-452.
32. Thomas SR, Pratt RG, Millard RW, Samaratunga RC, Shiferaw Y, Clark LC, Jr, Hoffmann RE. Evaluation of the influence of the aqueous phase bioconstituent environment on the F-19T1 of perfluorocarbon blood substitute emulsions. J. Magn. Reson. Imaging 1994; 4: 631-635.
33. 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn. Reson. Med. 2008; 60: 1066-1072.
34. Mitten RM, Burgan AR, Hamblin A, Yee G, Long DC, Long DM, Mattrey RF. Dose-related biodistribution and elimination of 100% PFOB emulsion. Biomater. Artif. Cells Artif. Organs 1988; 16: 683-684.
35. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994; 22: 1043-1054.
36. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv. Drug Deliv. Rev. 2001; 47: 209-228.
37. Shaw RF, Richard TJ. Rational development of Oxyfluor. In: Winslow R (ed.). Blood Substitutes. Academic Press: London, 2005; 298-311.
38. Keipert PE. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif. Cells Blood Substit. Immobil. Biotechnol. 1995; 23: 381-394.
39. 2 carrying perfluorochemical emulsions: toxicity, radiosensitivity of GM-CFC and development of metastases in mice. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 1153-1156.
40. Yokoyama K, Yamanouchi K, Ohyanagi H, Mitsuno T. Fate of perfluorochemicals in animals after intravenous injection or hemodilution with their emulsions. Chem. Pharm. Bull. (Tokyo) 1978; 26: 956-966.
41. Tsuda Y, Yamanouchi K, Yokoyama K, Suyama T, Watanabe M, Ohyanagi H, Saitoh Y. Discussion and considerations for the excretion mechanism of perfluorochemical emulsion. Biomater. Artif. Cells Artif. Organs 1988; 16: 473-483.
42. Yokoyama K, Yamanouchi K, Murashima R. Excretion of perfluorochemicals after intravenous injection of their emulsion. Chem. Pharm. Bull. (Tokyo) 1975; 23: 1368-1373.
43. Krafft MP, Riess JG, Weers JG. The design and engineering of oxygen-delivering fluorocarbon emulsions. In: Benita S (ed.). Submicronic Emulsions in Drug Targeting and Delivery. Harwood Academic Publishers: Amsterdam, 1998; 235-333.
44. Riess JG, Leblanc M. Solubility and transport phenomena in perfluorochemicals relevant to blood substitution and other biomedical applications. Pure Appl. Chem. 1982; 54: 2383-2406.
45. Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater. Artif. Cells Immobil. Biotechnol. 1992; 20: 183-202.
46. 19F magnetic resonance imaging. Invest. Radiol. 1988; 23: 361-364.
47. Weers JG. A physicochemical evaluation of perfluorochemicals for oxygen transport applications. J. Fluorine Chem. 1993; 64: 73-93.
48. Bruneton JN, Falewee MN, Francois E, Cambon P, Philip C, Riess JG, Balu-Maestro C, Rogopoulos A. Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. Radiology 1989; 170: 179-183.